<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00025090</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000068911</org_study_id>
    <secondary_id>NCRI-ACT-II</secondary_id>
    <secondary_id>EU-20056</secondary_id>
    <secondary_id>UKCCCR-ACT-II</secondary_id>
    <secondary_id>ISRCTN26715889</secondary_id>
    <nct_id>NCT00025090</nct_id>
  </id_info>
  <brief_title>Radiation Therapy Plus Fluorouracil With or Without Additional Chemotherapy in Treating Patients With Primary Anal Cancer</brief_title>
  <official_title>Second UK Phase III Anal Cancer Trial: A Trial of Chemoradiation and Maintenance Therapy for Patients With Anal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University College London (UCL) Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in&#xD;
      chemotherapy use different ways to stop tumor cells from dividing so they stop growing or&#xD;
      die. Combining chemotherapy with radiation therapy may kill more tumor cells. It is not yet&#xD;
      known if fluorouracil plus radiation therapy is more effective with or without additional&#xD;
      chemotherapy in treating anal cancer.&#xD;
&#xD;
      PURPOSE: Randomized phase III trial to compare the effectiveness of fluorouracil plus&#xD;
      radiation therapy with or without additional chemotherapy in treating patients who have&#xD;
      primary anal cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Compare the response rates in patients with primary epidermoid anal cancer treated with&#xD;
           radiotherapy and fluorouracil with either mitomycin or cisplatin and with or without&#xD;
           maintenance therapy.&#xD;
&#xD;
        -  Compare local control and prevention or delay of disease dissemination in patients&#xD;
           treated with these regimens.&#xD;
&#xD;
      OUTLINE: This is randomized, open-label, multicenter study. Patients are randomized to one of&#xD;
      four treatment arms.&#xD;
&#xD;
      All patients undergo radiotherapy daily 5 days a week for 5.5 weeks. All patients also&#xD;
      receive fluorouracil IV continuously over days 1-4 and 29-32.&#xD;
&#xD;
        -  Arm I: Patients receive mitomycin IV on day 1.&#xD;
&#xD;
        -  Arm II: Patients receive cisplatin IV on days 1 and 29.&#xD;
&#xD;
        -  Arm III: Patients receive mitomycin as in arm I and maintenance therapy comprising&#xD;
           fluorouracil IV continuously over days 1-4 and cisplatin IV on day 1 beginning 4-8 weeks&#xD;
           after completion of primary therapy and repeating once 3 weeks later.&#xD;
&#xD;
        -  Arm IV: Patients receive cisplatin as in arm II and maintenance therapy as in arm III.&#xD;
&#xD;
      Patients are followed at 2 months, every 3 months for 2 years, every 6 months for 3 years,&#xD;
      and then annually thereafter.&#xD;
&#xD;
      Peer Reviewed and Funded or Endorsed by Cancer Research UK&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 600 patients (150 per treatment arm) will be accrued for this&#xD;
      study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2001</start_date>
  <completion_date type="Actual">August 2007</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Complete response rate at 6 months</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Acute toxicity as measured up to 4 weeks after chemoradiation</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Recurrence-free survival</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Colostomy rate</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In field recurrence rate as measured by confirmed disease within radiation therapy field</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cause-specific and overall survival</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Anal Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fluorouracil</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mitomycin C</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed primary epidermoid anal cancer&#xD;
&#xD;
               -  Squamous cell&#xD;
&#xD;
               -  Basaloid&#xD;
&#xD;
               -  Cloacogenic&#xD;
&#xD;
          -  No adenocarcinoma, malignant melanoma, mucoepidermoid carcinoma, lymphoma, or&#xD;
             microinvasive anal intraepithelial neoplasia (without evidence of invasive disease) in&#xD;
             the anal canal or margin&#xD;
&#xD;
          -  No metastatic disease&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  0-2&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  WBC greater than 3,000/mm^3&#xD;
&#xD;
          -  Platelet count greater than 100,000/mm^3&#xD;
&#xD;
          -  Hemoglobin greater than 10 g/dL&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Liver function tests no greater than 2 times normal&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Glomerular filtration rate at least 50 mL/min&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  No cardiovascular disease&#xD;
&#xD;
          -  No uncontrolled angina pectoris&#xD;
&#xD;
          -  No heart failure&#xD;
&#xD;
          -  No clinically significant cardiac arrhythmias&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  No other significant concurrent illness&#xD;
&#xD;
          -  Not predominately bed-bound or frail&#xD;
&#xD;
          -  No severe sepsis&#xD;
&#xD;
          -  No other prior or concurrent cancer or illness that would preclude study participation&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  No prior radiotherapy to pelvis&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No prior therapy for anal cancer&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Roger D. James, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Maidstone Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Northwick Park Hospital</name>
      <address>
        <city>Harrow</city>
        <state>England</state>
        <zip>HA1 3UJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ipswich Hospital</name>
      <address>
        <city>Ipswich</city>
        <state>England</state>
        <zip>IP4 5PD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cookridge Hospital</name>
      <address>
        <city>Leeds</city>
        <state>England</state>
        <zip>LS16 6QB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Bartholomew's Hospital</name>
      <address>
        <city>London</city>
        <state>England</state>
        <zip>EC1A 7BE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Research UK and University College London Cancer Trials Centre</name>
      <address>
        <city>London</city>
        <state>England</state>
        <zip>NW1 2ND</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>James Cook University Hospital</name>
      <address>
        <city>Middlesbrough</city>
        <state>England</state>
        <zip>TS4 3BW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Vernon Cancer Centre at Mount Vernon Hospital</name>
      <address>
        <city>Northwood</city>
        <state>England</state>
        <zip>HA6 2RN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nottingham City Hospital</name>
      <address>
        <city>Nottingham</city>
        <state>England</state>
        <zip>NG5 1PB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Marsden - Surrey</name>
      <address>
        <city>Sutton</city>
        <state>England</state>
        <zip>SM2 5PT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southend University Hospital NHS Foundation Trust</name>
      <address>
        <city>Westcliff-On-Sea</city>
        <state>England</state>
        <zip>SS0 0RY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aberdeen Royal Infirmary</name>
      <address>
        <city>Aberdeen</city>
        <state>Scotland</state>
        <zip>AB25 2ZN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Velindre Cancer Center at Velindre Hospital</name>
      <address>
        <city>Cardiff</city>
        <state>Wales</state>
        <zip>CF14 2TL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Research Centre at Weston Park Hospital</name>
      <address>
        <city>Sheffield</city>
        <zip>S1O 2SJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>March 2007</verification_date>
  <study_first_submitted>October 11, 2001</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>August 23, 2013</last_update_submitted>
  <last_update_submitted_qc>August 23, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 26, 2013</last_update_posted>
  <keyword>stage I anal cancer</keyword>
  <keyword>stage II anal cancer</keyword>
  <keyword>stage IIIA anal cancer</keyword>
  <keyword>stage IIIB anal cancer</keyword>
  <keyword>squamous cell carcinoma of the anus</keyword>
  <keyword>cloacogenic carcinoma of the anus</keyword>
  <keyword>basaloid carcinoma of the anus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anus Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Mitomycins</mesh_term>
    <mesh_term>Mitomycin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

